16 January 2019 | News
CCRAS policy has provisions for Benchmarks for undertaking research/research consultation for already commercialized/marketed Ayurveda Products in the existing CCRAS Research Policy
In order to streamline and expedite the commercialization of ayurvedic drugs, Ayush ministry has approved CCRAS policy. Now, newly developed ayurvedic medications would reach pharmacy shelves at a quicker pace.
The guidelines prepared by the Central Council of Research in Ayurvedic Sciences (CCRAS) focus on transferring technology to industry, calculating royalty and resolving intellectual property rights issues. The new provisions for commercialising products, technologies and processes have been approved by Union minister of state for Ayush Shripad Naik.
CCRAS policy has provisions for Benchmarks for undertaking research/research consultation for already commercialized/marketed Ayurveda Products in the existing CCRAS Research Policy. Further, the Drugs, Technologies and process etc. developed by the Council are being commercialised through National Research Development Corporation (NRDC), New Delhi under Ministry of Science & Technology as per the provisions of Memorandum of Understanding entered with NRDC.
In view of expansion of the scope of R&D and its commercialisation as per the provisions of CCRAS Research Policy, different categories of the products / technologies and processes need to be transferred for further commercialisation.
In the last two years, the council has successfully commercialised products such as Ayush-82 for type –II diabetes and Ayush SG for rheumatoid arthritis. These formulations are already available in the market and are cost effective compared to other forms of therapy.